Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin to Boost Overseas Biz in Next 5 Years, Japan Market Unpredictable: President
February 2, 2016
- Astellas, Tohoku Univ. Spinoff Link Up on Gene Therapy for Retinitis Pigmentosa
February 2, 2016
- Sanofi Files Japan NDA for Plerixafor in Response to Govt Request
February 2, 2016
- Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
February 2, 2016
- Daiichi Sankyo to Continue Negotiations with FDA on Edoxaban Restriction: CEO
February 1, 2016
- Kyowa Kirin Enjoys 87% Profit Jump in 2015
February 1, 2016
- Kyowa Kirin to Forge Stand-Alone Sales Regime in US: 5 Year Plan
February 1, 2016
- Retooling Generic Business - 2: Mochida Seeks to Expand Alliances for Biosimilar Candidates
February 1, 2016
- FDA OKs Eisai’s Halaven for Liposarcoma
February 1, 2016
- Chugai Positions Mid-Sized Molecule Drugs as Third Pillar of Business, Aims to Produce First Candidate within 3 Years
February 1, 2016
- Chugai Foresees Tepid Growth for Next 3 Years: New Biz Plan
January 29, 2016
- Kadcyla Development for Gastric Cancer Discontinued: Chugai
January 29, 2016
- Chugai Delivers Record Earnings, but Pegasys Falters on IFN-Free Hep C Therapies
January 29, 2016
- Shionogi, Nissan Chemical Ink Collaboration Pact on Antifungals
January 29, 2016
- Sumitomo Dainippon to Revise 5-Year Business Plan
January 29, 2016
- Ferring Empowers Japan Unit, Local Head Mark Noggle Doubles as CEO
January 29, 2016
- Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
- Shionogi Files Japan NDA for ADHD Drug Licensed from Shire
January 28, 2016
- Mochida Seeks Adenomyosis Indication for Dinagest
January 28, 2016
- 140 Hep C Patients Receive Viekirax in 1st Month
January 27, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…